Questcor Demolishes the Short-Sellers
Questcor and its controversial flagship drug Acthar have come under fire from short sellers. The drug's many grandfathered indications and high pricing have made it an easy target as bears wait for a cheap competitor or insurer pushback. But they forgot one thing -- unless or until that happens, Questcor is a moneymaking machine.
In this video, health-care analyst David Williamson dives in to Questcor's second-quarter results in greater detail, discusses how dangerous it is to short a stock like Questcor, and talks about why this stock still may not be a good fit for Foolish investors.
One of the best parts of owning pharma stocks like Questcor is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
Follow David on Twitter: @MotleyDavid.
The article Questcor Demolishes the Short-Sellers originally appeared on Fool.com.
David Williamson owns shares of Novartis. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
